Mixed Phenotype Acute Leukemia, T/Myeloid, NOS

Diseases /

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS

Back to Diseases List

Associated Genetic Biomarkers

ABL1
ABL1 Fusion
ABL2
ABL2 Fusion
BCR
BCR-ABL1
BCR-ABL1 Fusion
CRLF2
CRLF2 Fusion
EPOR
EPOR Fusion
FGFR1
FGFR1 Fusion
FGFR2
FGFR2 Fusion
FGFR3
FGFR3 Fusion
FGFR4
FGFR4 Fusion
FLT3

FLT3 Fusion
IL7R
IL7R Mutation
JAK1
JAK1 Fusion
JAK1 Loss
JAK1 Mutation
JAK2
JAK2 Fusion
JAK2 Mutation

JAK3
JAK3 Fusion
JAK3 Mutation
LYN
LYN Fusion
NTRK1
NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3

NTRK3 Fusion
PDGFRA
PDGFRA Fusion
PDGFRB
PDGFRB Fusion
PTL2B fusion
SH2B3
SH2B3 Loss
SH2B3 Mutation
TYK2

TYK2 Fusion
t(9;22)(q34;q11)

Overview

NCI Definition: A rare mixed phenotype acute leukemia in which the blasts express T-lymphoid and myeloid lineage markers but are negative for MLL translocation and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable. [1]

Clinical Trials

View Clinical Trials for Mixed Phenotype Acute Leukemia, T/Myeloid, NOS

There is 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are completed or closed. Of the trial that contains mixed phenotype acute leukemia, T/myeloid, NOS as an inclusion criterion, 1 is phase 2/phase 3 (1 open).

ABL1, ABL2, and BCR-ABL1 are the most frequent gene inclusion criteria for mixed phenotype acute leukemia, T/myeloid, NOS clinical trials [3].

Trials Investigating Mixed Phenotype Acute Leukemia, T/Myeloid, NOS by Gene and Recruiting Status

Bortezomib, clofarabine, and cyclophosphamide are the most common interventions in mixed phenotype acute leukemia, T/myeloid, NOS clinical trials.

Drugs Being Investigated in Mixed Phenotype Acute Leukemia, T/Myeloid, NOS Trials by Recruiting Status

Significant Genes in Mixed Phenotype Acute Leukemia, T/Myeloid, NOS

ABL1 +

ABL1 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

ABL2 +

ABL2 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains ABL2 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains BCR status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CEP72 +

CEP72 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains CEP72 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CRLF2 +

CRLF2 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains CRLF2 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

EPOR +

EPOR is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains EPOR status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR1 +

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR2 +

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR3 +

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FGFR4 +

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

IL7R +

IL7R is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains IL7R status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK1 +

JAK1 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains JAK1 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK2 +

JAK2 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

JAK3 +

JAK3 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

LYN +

LYN is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains LYN status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK1 +

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK2 +

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

NTRK3 +

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

PDGFRB +

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

SH2B3 +

SH2B3 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains SH2B3 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

TYK2 +

TYK2 is an inclusion eligibility criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains TYK2 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

Disease Details

Synonyms

Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified

Parent(s)

Mixed Phenotype Acute Leukemia

OncoTree Name

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS

OncoTree Code

MPALTNOS

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Mixed Phenotype Acute Leukemia, T/Myeloid, NOS

Disease Details

References

About

Molecular Medicine

Content Types